NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports First-Half 2026 Results, Advances Expanded U.S. Clinical Manufacturing Program
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company combining therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), reported first-half 2026 revenue of $949,000, up from $773,000 in the prior-year period, while committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including approximately $2.1 million already invoiced. The company is also advancing an expanded clinical manufacturing and chemistry, manufacturing and controls (“CMC”) program for a U.S.-based biopharmaceutical company, with approximately $650,000 in cash payments and advances received and substantive activities underway while a definitive agreement remains under negotiation. The program is intended to support an investigational…







